{"brief_title": "Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL)", "brief_summary": "The objective of this study is to assess the efficacy and safety of talabostat and rituximab in patients with advanced CLL who failed to respond, or have progressed following a prior response, to a fludarabine regimen.", "detailed_description": "Completion date provided represents the completion date of the grant per OOPD records", "condition": ["Chronic Lymphocytic Leukemia"], "intervention_type": ["Drug", "Drug"], "intervention_name": ["Talabostat mesylate (PT-100) tablets", "Rituximab"], "criteria": "INCLUSION CRITERIA: - Men or women \u226518 years of age - Histopathologically confirmed diagnosis of B-CLL expressing surface CD20 of any detectable intensity - Rai Stage III or IV. Rai Stages I and II with massive or progressive lymphadenopathy or hepatosplenomegaly. - Primary resistance to a fludarabine regimen (no PR or CR) or progressive disease within 1 year of a prior response - ECOG performance status 0, 1, or 2 - Written informed consent EXCLUSION CRITERIA: - Therapy for CLL within 4 weeks of Study Day 1 (including chemotherapy, radiation, immunotherapy, cytokine or biologic [with the exception of hematopoietic growth factors]). Patients must have recovered from the adverse effects of prior therapy. - Known primary or secondary malignancy of the central nervous system - Any malignancy within the 5 years immediately prior to the first dose of study medication with the exception of basal cell or non-metastatic squamous cell carcinoma of the skin, and carcinoma in-situ of the cervix - Serum creatinine >2.0mg/dL (>176 micromol/L) - AST or ALT \u22653 x the upper limit of normal (ULN) - Total bilirubin \u22651.5 x ULN (unless secondary to Gilbert's) - Positive serology for hepatitis B (HBsAg) or hepatitis C (anti-HCV antibody) - Known positivity for HIV - Prior organ allograft - Concurrent comorbid medical conditions that, in the opinion of the investigator, preclude the safe delivery of the experimental treatment - Pregnant or nursing women", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "mesh_term": ["Leukemia", "Leukemia, Lymphoid", "Leukemia, Lymphocytic, Chronic, B-Cell", "Rituximab"], "id": "NCT00086203"}